Evolving Landscape of Glioma: A Focus on IDH-Mutant Gliomas
Vinay K. Puduvalli, MD, explores recent advances in glioma classification and treatment, discussing the impact of new WHO guidelines, molecular markers, clinical trials, and emerging therapies like IDH inhibitors on patient care strategies, while identifying persisting challenges and future research priorities in neuro-oncology.
EP. 1: Real-World Clinical Practice: Challenges With Glioma Management
November 4th 2024Panelists discuss how the updated WHO classification system for gliomas has impacted their treatment approaches, while also addressing the practical difficulties of integrating these changes into routine clinical care.
EP. 2: Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas
November 11th 2024Panelists discuss how they tailor treatment strategies for oligodendrogliomas and Grade 2 gliomas based on key clinical and molecular markers, with particular attention to insights from the CODEL trial and RTOG 9802 study.
EP. 4: IDH Inhibitors in the Treatment of Low-Grade Gliomas
November 25th 2024Panelists discuss how IDH inhibitors such as ivosidenib could potentially reshape the treatment approach for low-grade gliomas, while also exploring what further clinical evidence would be necessary to confidently integrate these novel agents into standard care protocols.
EP. 5: INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas
December 2nd 2024Panelists discuss how the INDIGO trial results and vorasidenib's approval could shift treatment paradigms for IDH-mutant low-grade gliomas, weighing various clinical, molecular, and patient-specific factors when considering the integration of this novel targeted therapy into individualized treatment plans.
